Table 5.

Outcome of sarcoidosis patients infected with COVID-19 versus immunosuppressive therapy*

DRUG	Home	Hospital	Percent in hospital	HR	95% CI	p
All patients	86	19	18.1%
Prednisone
Yes	29	5	14.7%	0.75	0.293-1.901	>0.10
No	57	14	19.7%
If prednisone
Prednisone > 10 mg	13	2	13.3%	0.76	0.186-3.106	>0.10
Prednisone < 10mg	47	10	17.5%
anti-TNF monoclonal antibodies (infliximab, adalmumab)
Yes	5	2	28.6%	1.65	0.473-5.740	>0.10
No	81	17	17.3%
Hydroxychloroquine
Yes	7	1	12.5%	0.67	0.103-4.416	>0.10
No	79	18	18.6%
Cytotoxic (methotrexate, azathioprine, mycophenolate, leflunomide)
Yes	17	7	29.2%	1.97	0.873-4.440	>0.10
No	69	12	14.8%
Rituximab
Yes	6	1	14.3%	0.78	0.121-5.006	>0.10
No	80	18	18.4%

*Data not available on all patients.

HR: hazard ratio; anti-TNF: anti-tumor necrosis factor antibody;